Profile
David M.
Spencer was the founder of Bellicum Pharmaceuticals, Inc. founded in 2004, where he held the title of Chief Technology Officer from 2018 to 2019.
He also held the position of Professor and Vice Chairman-Pathology & Immunology at Baylor College of Medicine and was the Director & Chief Scientific Officer at Kiromic Biopharma, Inc. Dr. Spencer earned a doctorate degree from the Massachusetts Institute of Technology and an undergraduate degree from the University of California San Diego.
Former positions of David M. Spencer
| Companies | Position | End |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Founder | 2019-02-28 |
| KIROMIC BIOPHARMA, INC. | Chief Tech/Sci/R&D Officer | - |
| Baylor College of Medicine | Corporate Officer/Principal | - |
Training of David M. Spencer
| Massachusetts Institute of Technology | Doctorate Degree |
| University of California San Diego | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| KIROMIC BIOPHARMA, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
- Stock Market
- Insiders
- David M. Spencer
